GlobeNewsWire
29 Jul 2026, 10:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Eton Pharmaceuticals has submitted a Prior Approval Supplement (PAS) to the FDA to expand the KHINDIVI label to include pediatric patients under age five. — Expanding the target patient demographic to the largest underserved group (children under five) significantly increases the total addressable market and revenue potential.
+0.60The company's new formulation demonstrated bioequivalence to ALKINDI SPRINKLE, an FDA-approved hydrocortisone granule formulation. — Proving bioequivalence to an existing approved product reduces the clinical risk and increases the likelihood of FDA approval for the expanded label.
+0.40The company expects a potential label expansion in the first half of 2027. — Provides a clear timeline for a catalyst event, though the distance of the date limits immediate price volatility.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company submitted a Prior Approval Supplement to expand the label of KHINDIVI to younger pediatric patients, representing a key strategic milestone.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
